221 related articles for article (PubMed ID: 15370686)
1. Enhanced glucose-dependent glucagon-like peptide-1 and insulin secretion in Crohn patients with terminal ileum disease is unrelated to disease activity or ileal resection.
Bendet N; Scapa E; Cohen O; Bloch O; Aharoni D; Ramot Y; Weiss M; Halevi A; Rapoport MJ
Scand J Gastroenterol; 2004 Jul; 39(7):650-6. PubMed ID: 15370686
[TBL] [Abstract][Full Text] [Related]
2. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.
Nauck MA; El-Ouaghlidi A; Gabrys B; Hücking K; Holst JJ; Deacon CF; Gallwitz B; Schmidt WE; Meier JJ
Regul Pept; 2004 Nov; 122(3):209-17. PubMed ID: 15491793
[TBL] [Abstract][Full Text] [Related]
3. Elevated plasma levels of glucagon-like peptide-1 after oral glucose ingestion in patients with pancreatic diabetes.
Hiroyoshi M; Tateishi K; Yasunami Y; Maeshiro K; Ono J; Matsuoka Y; Ikeda S
Am J Gastroenterol; 1999 Apr; 94(4):976-81. PubMed ID: 10201468
[TBL] [Abstract][Full Text] [Related]
4. Release of glucagon-like peptide 1 (GLP-1 [7-36 amide]), gastric inhibitory polypeptide (GIP) and insulin in response to oral glucose after upper and lower intestinal resections.
Nauck MA; Siemsglüss J; Orskov C; Holst JJ
Z Gastroenterol; 1996 Mar; 34(3):159-66. PubMed ID: 8650968
[TBL] [Abstract][Full Text] [Related]
5. Enhanced glucagon-like peptide-1 (GLP-1) response to oral glucose in glucose-intolerant HIV-infected patients on antiretroviral therapy.
Andersen O; Haugaard SB; Holst JJ; Deacon CF; Iversen J; Andersen UB; Nielsen JO; Madsbad S
HIV Med; 2005 Mar; 6(2):91-8. PubMed ID: 15807714
[TBL] [Abstract][Full Text] [Related]
6. Changes in glucagon-like peptide-1 (GLP-1) secretion after biliopancreatic diversion or vertical banded gastroplasty in obese subjects.
Valverde I; Puente J; Martín-Duce A; Molina L; Lozano O; Sancho V; Malaisse WJ; Villanueva-Peñacarrillo ML
Obes Surg; 2005 Mar; 15(3):387-97. PubMed ID: 15826475
[TBL] [Abstract][Full Text] [Related]
7. Orally administered glucagon-like peptide-1 affects glucose homeostasis following an oral glucose tolerance test in healthy male subjects.
Steinert RE; Poller B; Castelli MC; Friedman K; Huber AR; Drewe J; Beglinger C
Clin Pharmacol Ther; 2009 Dec; 86(6):644-50. PubMed ID: 19727071
[TBL] [Abstract][Full Text] [Related]
8. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.
Vollmer K; Holst JJ; Baller B; Ellrichmann M; Nauck MA; Schmidt WE; Meier JJ
Diabetes; 2008 Mar; 57(3):678-87. PubMed ID: 18057091
[TBL] [Abstract][Full Text] [Related]
9. Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1.
Nauck MA; Walberg J; Vethacke A; El-Ouaghlidi A; Senkal M; Holst JJ; Gallwitz B; Schmidt WE; Schmiegel W
Regul Pept; 2004 Apr; 118(1-2):89-97. PubMed ID: 14759561
[TBL] [Abstract][Full Text] [Related]
10. Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect.
Prigeon RL; Quddusi S; Paty B; D'Alessio DA
Am J Physiol Endocrinol Metab; 2003 Oct; 285(4):E701-7. PubMed ID: 12773303
[TBL] [Abstract][Full Text] [Related]
11. Effect of growth hormone on high plasma levels of glucagon-like peptide-1 (GLP-1) in hypophysectomized rats.
Tateishi K; Kitayama N; Ishikawa H; Mitsudome A; Hirose S
Exp Clin Endocrinol Diabetes; 2002 Oct; 110(7):361-3. PubMed ID: 12397536
[TBL] [Abstract][Full Text] [Related]
12. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
Hücking K; Kostic Z; Pox C; Ritzel R; Holst JJ; Schmiegel W; Nauck MA
Diabet Med; 2005 Apr; 22(4):470-6. PubMed ID: 15787675
[TBL] [Abstract][Full Text] [Related]
13. Impaired circulating glucagon-like peptide-1 response to oral glucose in women with previous gestational diabetes.
Forbes S; Moonan M; Robinson S; Anyaoku V; Patterson M; Murphy KG; Ghatei MA; Bloom SR; Johnston DG
Clin Endocrinol (Oxf); 2005 Jan; 62(1):51-5. PubMed ID: 15638870
[TBL] [Abstract][Full Text] [Related]
14. Early improvement of glucose tolerance after ileal transposition in a non-obese type 2 diabetes rat model.
Patriti A; Facchiano E; Annetti C; Aisa MC; Galli F; Fanelli C; Donini A
Obes Surg; 2005 Oct; 15(9):1258-64. PubMed ID: 16259883
[TBL] [Abstract][Full Text] [Related]
15. Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion.
Lugari R; Dei Cas A; Ugolotti D; Barilli AL; Camellini C; Ganzerla GC; Luciani A; Salerni B; Mittenperger F; Nodari S; Gnudi A; Zandomeneghi R
Horm Metab Res; 2004 Feb; 36(2):111-5. PubMed ID: 15002062
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-like peptide-1 secretion is influenced by perfusate glucose concentration and by a feedback mechanism involving somatostatin in isolated perfused porcine ileum.
Hansen L; Hartmann B; Mineo H; Holst JJ
Regul Pept; 2004 Apr; 118(1-2):11-8. PubMed ID: 14759551
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like peptide 2 inhibits ghrelin secretion in humans.
Banasch M; Bulut K; Hagemann D; Schrader H; Holst JJ; Schmidt WE; Meier JJ
Regul Pept; 2006 Dec; 137(3):173-8. PubMed ID: 16928403
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-like peptide-1 reduces the pulsatile component of testosterone secretion in healthy males.
Jeibmann A; Zahedi S; Simoni M; Nieschlag E; Byrne MM
Eur J Clin Invest; 2005 Sep; 35(9):565-72. PubMed ID: 16128863
[TBL] [Abstract][Full Text] [Related]
19. Involvement of endogenous glucagon-like peptide-1(7-36) amide on glycaemia-lowering effect of oligofructose in streptozotocin-treated rats.
Cani PD; Daubioul CA; Reusens B; Remacle C; Catillon G; Delzenne NM
J Endocrinol; 2005 Jun; 185(3):457-65. PubMed ID: 15930172
[TBL] [Abstract][Full Text] [Related]
20. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP.
Theodorakis MJ; Carlson O; Michopoulos S; Doyle ME; Juhaszova M; Petraki K; Egan JM
Am J Physiol Endocrinol Metab; 2006 Mar; 290(3):E550-9. PubMed ID: 16219666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
